What Makes Flexible Bag Integrity Testing Difficult in Pharmaceutical Manufacturing｜Key Points of Bag Integrity Testers

In recent years, with the rapid advancement of biopharmaceutical technologies such as monoclonal antibodies, vaccines, and cell and gene therapies, Single‑Use Systems (SUS) have been increasingly widely adopted in pharmaceutical manufacturing.

Compared with traditional stainless‑steel equipment, single‑use bioprocess consumables offer advantages including reduced cleaning validation, lower cross‑contamination risks and improved production flexibility. Hence, they are extensively deployed in multiple manufacturing stages such as buffer storage, media preparation, liquid transfer and material mixing. Single‑use liquid storage bags, mixing bags, media bags and other flexible bioprocess bags serve as critical components within single‑use systems.

Manufactured from multi‑layer polymeric films, flexible bags feature soft and deformable properties. During transportation, storage, sterilization, connection and operation, both the bag body and welded joints may be compromised, creating potential leakage hazards. Consequently, integrity testing for single‑use bioprocess bags has become an essential practice to secure production continuity, mitigate contamination risks and satisfy quality management requirements.

Why Is Integrity Testing Mandatory for Single‑Use Bioprocess Bags?

Throughout their lifecycle covering manufacturing, packaging, shipment, warehousing and on‑site installation, single‑use bioprocess bags are exposed to mechanical stress and environmental factors that may induce latent defects in bag films, heat‑sealed zones and connector assemblies.

For biopharmaceutical manufacturers, integrity failures of flexible bags go far beyond simple packaging leakage; they may jeopardize the reliability of the entire production workflow. In aseptic manufacturing environments, micro‑defects invisible to visual inspection can allow ingress of microorganisms or particulate matter from the external environment, posing risks to subsequent production runs. Furthermore, single‑use bags hold critical materials such as culture media and buffer solutions. In‑process leakage will not only result in material loss but also trigger production downtime and elevated batch‑failure risks.

Reliance solely on supplier certificates of quality or manual visual inspection can no longer fully meet modern biopharmaceutical quality control standards for single‑use consumables. Conducting integrity verification on flexible packaging before production deployment via validated testing methods is vital for risk reduction.

Why Is Integrity Testing of Flexible Bags More Complex Than Rigid Packaging Testing?

From a technical perspective, the core challenge of flexible‑bag integrity testing lies not in the fundamental test principle itself, but in reliably distinguishing genuine leakage signals from pressure fluctuations caused by material deformation.

Rigid containers such as glass vials and metallic vessels undergo minimal structural variation under pressurization. Pressure changes measured during testing primarily stem from gas‑state variations inside the package. By contrast, flexible bags made of elastic polymeric films expand, stretch and rebound dynamically as internal pressure fluctuates. This elastic material response distorts pressure profiles, demanding highly precise test‑cycle control. Rapid gas inlet leads to abrupt bag expansion and drastic material stress shifts; unstable pressure regulation may trigger abnormal pressure fluctuations. These variables introduce measurement deviations and raise the probability of false test results.

Therefore, integrity testing protocols for flexible bags must comprehensively correlate bag dimension, material characteristics, structural design and test parameters. Test workflows for rigid packaging cannot be directly reused.

Where Do the Main Integrity Risks Occur on Flexible Bags?

A single‑use bioprocess bag is an assembled system comprising the film body, welded seams, tubing assemblies and connecting ports. While the bag film itself generally maintains robust integrity, weld lines and connection ports represent the predominant high‑risk zones for potential failure.

Unstable thermal sealing parameters during fabrication may generate micro‑defects in welded regions. Mechanical impact during logistics and handling can compromise connector integrity, and improper on‑site manipulation may cause localized damage. These imperfections are often undetectable via visual examination yet may develop into functional leaks during storage or production. Accordingly, integrity testing shall cover the complete packaging system rather than limited visual checks of the bag surface.

Application of Pressure‑Decay Testing for Flexible‑Bag Integrity Verification

Multiple analytical techniques have been established for container closure integrity testing, including visual inspection, water‑bath bubble testing, vacuum decay and pressure decay methods. Featuring non‑destructive operation, quantifiable results and compatibility with flexible packaging, the pressure‑decay technique has gained growing acceptance for single‑use bioprocess bag testing.

The core principle of pressure‑decay testing is as follows: introduce compressed air into the test specimen until a stable set pressure is achieved, then continuously monitor pressure evolution throughout the hold phase. If the packaging contains a leak, internal gas escapes through the defect, resulting in a measurable pressure drop. The instrument evaluates pressure‑trend data against predefined acceptance criteria to determine integrity status.

For flexible bags, optimizing pressure‑decay testing requires more than high‑precision sensors. It is critical to counteract measurement interference originating from material deformation. Practical testing workflows demand holistic optimization of gas‑inlet profiles, pressure regulation, stabilization duration and analytical algorithms. This enables the tester to differentiate authentic leakage signals from pressure artefacts induced by the physical behaviour of flexible films.

Neuronbc BGT‑200 Bag Integrity Tester: A Dedicated Solution for Flexible Packaging Testing

To address measurement interferences from material deformation, test stability challenges and end‑to‑end data governance requirements for single‑use bioprocess bags, Neuronbc has developed the BGT‑200 Bag Integrity Tester. Built upon the pressure‑decay principle, this instrument is systematically optimised for large‑format flexible packaging. Regulated gas‑inlet control mitigates measurement bias caused by excessive bag expansion and enhances overall test stability.

The BGT‑200 is suitable for integrity verification across a wide range of flexible packaging formats: single‑use storage bags, media bags, bioprocess mixing bags, pharmaceutical flexible containers and intravenous infusion bags. It empowers manufacturers to complete quality confirmation prior to material dispensing for production and reduce operational risks triggered by packaging defects. Equipped with test‑data logging, user permission management and audit‑tracking functionality, the instrument satisfies pharmaceutical traceability requirements. Corresponding validation documentation supports deployment within GMP‑controlled environments.

As a foundational element of modern biomanufacturing workflows, single‑use bioprocess bags directly govern process stability and product‑quality risk mitigation. With the expanding adoption of single‑use technologies across biopharma, flexible‑bag integrity testing has evolved from a simple pass‑fail leak check into a key control node linking consumable quality management, in‑process monitoring and regulatory compliance.

Application of stable, robust and traceable test solutions tailored for flexible packaging will further strengthen the reliability of single‑use manufacturing platforms and deliver comprehensive quality assurance for pharmaceutical production.